3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Phase 1
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
19
Head & Neck
7
Dermatologic
6
Gastrointestinal
5
Thoracic
4
Sarcoma
4
Genitourinary
4
Endocrine
3
CNS
3
Gynecologic
2
Breast
2
Other solid neoplasm
1
NET
1
Conditions
Neuroendocrine Tumors
169
Carcinoid Tumor
27
Carcinoma, Neuroendocrine
22
Neoplasms
16
Gastro-enteropancreatic neuroendocrine tumor
16
Adenoma, Islet Cell
15
Pancreatic Neoplasms
12
Neoplasm Metastasis
10
Pheochromocytoma
8
Paraganglioma
8
Sarcoma
7
Colorectal Neoplasms
7
Carcinoma
7
Neuroectodermal Tumors, Primitive
6
Neuroblastoma
6
Gastrointestinal Neoplasms
6
Vipoma
5
Somatostatinoma
5
Gastrinoma
5
Cholangiocarcinoma
5
Carcinoma, Islet Cell
5
Breast Neoplasms
5
Small Cell Lung Carcinoma
4
Serotonin Syndrome
4
Digestive System Neoplasms
4
Anus Neoplasms
4
Thyroid Neoplasms
3
Salivary Gland Neoplasms
3
Ovarian Neoplasms
3
Neoplasms by Site
3
Interventions
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Unknown Primary
×
NET
×
Clear all
NCT04276597
2023-03-10
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Phase 2
Withdrawn